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Abstract:
Inferring genetic networks from gene expression data is one of the most challenging work in the post-genomic era,
partly due to the vast space of possible networks and the relatively small amount of data available. In this field,
Gaussian Graphical Model (GGM) provides a convenient framework for the discovery of biological networks.
In this paper, we propose an original approach for inferring gene regulation networks using a robust biological prior on
their structure in order to limit the set of candidate networks.
Pathways, that represent biological knowledge on the regulatory networks, will be used as an informative prior
knowledge to drive Network Inference. This approach is based on the selection of a relevant set of genes, called the
“molecular signature”, associated with a condition of interest (for instance, the genes involved in disease development).
In this context, differential expression analysis is a well established strategy. However outcome signatures are often not
consistent and show little overlap between studies. Thus, we will dedicate the first part of our work to the improvement
of the standard process of biomarker identification to guarantee the robustness and reproducibility of the molecular
signature.
Our approach enables to compare the networks inferred between two conditions of interest (for instance case
and control networks) and help along the biological interpretation of results. Thus it allows to identify differential
regulations that occur in these conditions. We illustrate the proposed approach by applying our method to a study of
breast cancer’s response to treatment.
Résumé :
L’inférence de réseaux génétiques à partir de données issues de biopuces est un des défis majeurs de l’ère post-
génomique, en partie à cause du grand nombre de réseaux possibles et de la quantité relativement faible de données
disponibles. Dans ce contexte, la théorie des modèles graphiques gaussiens est un outil efficace pour la reconstruction
de réseaux.
A travers ce travail nous proposons une approche d’inférence de réseaux de régulation à partir d’un a priori biologique
robuste sur la structure des réseaux afin de limiter le nombre de candidats possibles.
Les voies métaboliques, qui rendent compte des connaissances biologiques des réseaux de régulation, nous per-
mettent de définir cet a priori. Cette approche est basée sur la sélection d’un ensemble de gènes pertinents, appelé
“signature moléculaire”, potentiellement associé à un phénotype d’intérêt (par exemple les gènes impliqués dans le
développement d’une pathologie). Dans ce contexte, l’analyse différentielle est la strategie prédominante. Néanmoins
les signatures de gènes diffèrent d’une étude à l’autre et la robustesse de telles approches peut être remise en question.
Ainsi, la première partie de notre travail consistera en l’amélioration de la stratégie d’identification des gènes les plus
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informatifs afin de garantir la robustesse et la reproductibilité de la signature moléculaire.
Notre approche vise à comparer les réseaux inférés dans différentes conditions d’étude et à faciliter l’interprétation
biologique des résultats. Ainsi, elle permet de mettre en avant des régulations différentielles entre ces conditions.
Nous appliquerons notre méthode à l’étude de la réponse au traitement dans le cancer du sein.
Keywords: Network Inference, Gaussian Graphical Model, `1 penalization, Prior information, Pathway Analysis
Mots-clés : Inférence de réseaux, Modèle graphique gaussien, Pénalisation `1, Information a priori, Analyse de voies
métaboliques
AMS 2000 subject classifications: 60K35,
1. Introduction
Advances in Molecular Biology and substantial improvements in microarray technology have
led biologists toward high-throughput genomic studies. It has become possible to detect tens of
thousands of genes and compare their expression levels between samples in a single experiment.
These data describe dynamic changes in gene expression closely related to regulatory events with-
out offering any explanation on how this is all managed by the genome. The use of microarrays to
discover differentially expressed genes between two or more conditions (patients versus controls
for instance) has found many applications. These include the identification of disease biomarkers
(i.e. the genes potentially associated with a given disease) that may be important in the diagnosis
of the different types or subtypes of diseases. A common challenge faced by the researchers is to
translate the identified sets of differentially expressed genes into a better understanding of the
underlying biological phenomena.
A wealth of analysis tools are available among which Pathway Analysis and Network Inference
are getting especially popular in the field of gene expression data analysis. They both hold great
promise to interpret genome-wide profile.
Pathways can be defined as sets of gene products interacting in order to achieve a specific
cellular function (cell cycle or apoptosis for instance). Pathway Analysis aims at determining
whether the set of differentially expressed genes is “enriched” by a given pathway or cellular func-
tion. Pathway Analysis approaches have the advantage of providing a clear and direct biological
interpretation. However it can appear restrictive as pathways represent a strong biological prior
and results will not deviate from our current knowledge of the cellular mechanisms.
On the other side, the purpose of Network Inference is to predict the presence or absence of
edges between a set of genes known to form the vertices of a network, the prediction being based
on gene expression levels. Various statistical frameworks have been proposed to solve the network
inference problem [7, 33]. Graphical models such as Bayesian network [9] and constraint-based
methods are popular frameworks to model the gene regulatory networks. Modelings with the
Boolean networks [14, 17, 25, 30] or differential equations have also been investigated.
Discovering structures of regulation networks based on large-scale data represents a major chal-
lenge in Systems Biology, partly because the space of possible networks is often too large
compared to the relatively small amount of data available. Moreover, exploring all possible
network topologies is not computationally feasible. However, all the networks are not equally
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plausible and the use of biological knowledge may help to limit the set of candidate networks.
Little research have already been made to associate biological informative prior to Network
Inference in a Bayesian network framework [19] or by the use of dynamic Bayesian networks [3]
from time series data. In the field of Machine Learning other kinds of approaches have been
proposed based on kernel metric learning [32, 35].
In this paper, we propose a 3-step approach to define a biological prior on network structure
to drive the Network Inference. Our intention here is to overcome both Pathway Analysis and
Network Inference limitations by integrating these two approaches.
We will dedicate the first part of our work to the improvement of the standard process of biomarker
identification to guarantee the robustness and reproducibility of the gene signature. Indeed due
to the biological and technical variability within the expression data, robust gene selection is a
crucial issue. Most informative genes have to be identified to ensure the inference of a relevant
network.
The second step consists in correlating the signature with a priori defined gene sets from biological
pathway databases. The resulting metabolic and signaling pathways will be used as an informative
prior in the last step.
Finally, a network is inferred with the idea to encourage the inference of an edge between two
genes when they are known to participate to the same cellular function. A way to describe the
interactions among the genome functional elements is by using conditional independencies and,
more concretely, graphical models [16, 23, 34] which provide a convenient setting for inferring
gene regulatory networks. We base our approach on this strategy implemented in the R package
SIMoNe (Statistical Inference for Modular Network) [5] which enables inference of undirected
networks based on partial correlation. In this approach, Chiquet et al presents the first method
dedicated to the inference of multiple graphs. In other words, when various experimental condi-
tions are available, they propose to estimate multiple GGMs jointly, in a multi-task framework by
coupling the estimation of several networks.
We conduct our global approach on breast cancer data to identify the molecular mechanisms
underlying the response to treatment using the cohort from Hess et al. 2006 [11] by comparing
the networks inferred under 2 conditions: patients who achieve pathological complete response
(pCR) and those who do not (not-pCR).
2. Materials and Methods
The purpose of this work is to provide a global framework for transcriptomic data analysis
and in particular for inferring co-expression networks from a relevant biological informative
prior based on Pathway Analysis. The co-expression networks are seen as regulation networks
for which the direction of the edges and hence causality events are not known. Such analyses
require as a preliminary step to select the genes involved in the phenotype of interest that are
assumed to be differentially expressed between the conditions to compare. This selection is of
great importance since the results of Pathway Analysis and Network Inference directly depend
upon it.
Hence, our global approach can be viewed as a 3-step process: i) an improved selection of
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differentially expressed genes ii) a Pathway Analysis and iii) a Network Inference strategy using
Pathway Analysis results as an informative biological prior. These 3 steps are fully described
below and summarized in Figure 1.
Normalized 
data 
Robust gene selec4on 
A priori construc4on from 
pathway analysis 
Network inference 
Step 1 
Step 2 
Step 3 
Figure 1. Global approach of expression data analysis. Our approach follows a 3-step
process: from the expression data we first perform a robust selection to identify the most
informative genes, called the signature. Then, we define the biological prior by conducting a
Pathway Analysis on the gene signature. The last step consists in inferring a network driven by
the prior defined at the previous step.
Let us first introduce some notations. We consider hereafter a sample of a random vectors
Xcr = (X1cr, . . . ,X
p
cr) where X icr is the level of expression observed for gene i, replicate r, under
condition c; The vector Xcr is assumed to be Gaussian with positive definite covariance matrix
Σc = (Σci j)(i, j)∈P2 whereP = {1, . . . , p}. No loss of generality is involved when centering Xcr,
so we may assume that Xcr ∼N (0p,Σc).
Step1: Gene selection by robust differential analysis
Given two conditions to compare (called condition 1 et condition 2 in the following), a key
question in the first step of expression data analysis is to identify a set of genes that shows a
differential expression between the two conditions of interest. This consists, for each gene, in
testing the null hypothesis (H0) that the expected values of expression are equal between the two
conditions, against the alternative hypothesis (H1) that they differ. The general model is then
given by:
E(X icr) = µ ic and Var(X icr) = (σ ic)2.
So defined, the null hypothesis to test comes down to:{
H0 : µ i1 = µ
i
2,
H1 : µ i1 6= µ i2.
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At first glance, differential analysis appears easy enough but in practice results from differential
analysis show a lack of reproducibility when compared in the literature [8]. In fact, due to the
biological and technical noise inherent to high-throughput biological data, methodological aspects
are still to investigate to obtain a more robust selection of differentially expressed genes. To do so
we propose several methodological improvements to the strategy commonly used, that is generally
reduced to the application of a t-test.
If the t-test is certainly the most natural and popular test to assess differential expression,
its efficacy in term of variance modeling and power on small sample sizes has been seriously
questioned. The recent study from Jeanmougin et al. [12] demonstrates that the Bayesian
framework proposed by limma [26] outperforms all the usual methods to test for differential
expression. Briefly, limma has the same interpretation as an ordinary t-statistic except that the
standard errors have been moderated across genes:
t ilimma =
x¯i1·− x¯i2·
Si
√
1
n1
+ 1n2
,
where n1 and n2 are number of replicates of conditions 1 and 2 and x¯i1· is the average expression
level for gene i and condition 1 (across all possible replicates).
Indeed, posterior variance, Si, has been substituted into the classical t-statistic in place of the
usual variance. Using Bayes rules, this posterior variance becomes a combination of an estimate
obtained from a prior distribution and the pooled variance. Including a prior distribution on vari-
ances has the effect of borrowing information from the ensemble of the genes to aid with inference
about each individual gene. Thus, the posterior values shrink the observed variances towards a
common value, that is why it is called “moderated” t-statistic. This approach is implemented in
the R package limma.
Despite the use of limma, such a hypothesis testing strategy to select differentially expressed
genes between 2 conditions can be biased by outliers. In this context, re-sampling based ap-
proaches are pretty common methods. Here, we use random forest [4] for improving the overall
homogeneity of the signature obtained from differential analysis. The algorithm consists in
fitting many binary decision trees built using several bootstrap samples and then in combining the
predictions from all the trees. Random forest uses both bagging and random variable selection
for tree building. Thus, at each node, a given number of input variables are randomly chosen
and the best split is calculated only within this subset. The Out-Of-Bag sample (i.e. the set of
observations which are not used for building the current tree) is used to estimate the prediction
error and then to evaluate variable importance.
We apply Random Forest algorithm (implemented in the R package randomForest) to rank
the significant genes resulting from limma according to variable importance (i.e ability to well
discriminate the conditions). This approach enables to clean the set of differentially expressed
genes from putative outliers by selecting most important variables. A simple Principal Component
Analysis of the samples before and after the application of the Random Forest algorithm clearly
show how it increases the separation of the conditions (Figure 2).
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Figure 2. Improving discrimination between conditions using Random Forests. A Principal
Component Analysis is performed on conditions of interest. The signature obtained by Random
Forest (RF) algorithm enables to better discriminate condition 1 from condition 2 as shown in the
figures before and after running the RF.
Finally little agreement between studies in the literature is also due to the heterogeneity inherent
to genetic diseases and to sampling variation for moderate sample size. Thus, two differential
analyses based on two different studies may lead to different selection of genes, however resulting
from the same regulatory process. Motivated by the observation that genes causing the same
phenotype are likely to be functionally related [10, 15] (i.e they form some kind of module [21],
for instance a multi-protein complex), we explore a network-based approach to identify modules
of genes rather than individual genes. We will refer to this approach as “functional partners
identification” in the following. One of the strongest manifestation of a functional relation between
genes is Protein-Protein Interaction (PPI). Oti et al. [22] demonstrated that exploiting PPIs can
lead to novel candidate gene prediction. While many PPI network databases are available, such as
Ingenuity Pathway Analysis (Ingenuity® Systems, www.ingenuity.com) or STRING [27],
few studies have actually integrated such knowledge for biomarkers identification.
The PPI network was extracted using STRING. The interactions include direct (physical) and
indirect (functional) associations derived from various sources on the basis of both experimental
evidence for PPIs as well as interactions predicted by comparative genomics and text mining.
STRING uses a scoring system that is intended to reflect the evidence of predicted interactions.
In the present study, we add the relevant functional partners with a score of at least 0.9 (which
corresponds to a high-confidence network) to the set of differentially expressed genes.
In the following, our final set of genes will be called the "molecular signature" of the conditions
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to compare.
Step2: Pathway Analysis to define a robust a priori
Pathway Analysis aims at identifying the cellular processes involved in differentiating the two
conditions to compare (cases and controls for instance) in order to enhance the interpretation of
the molecular signature generated at step 1.
In practice, Pathway Analysis consists in determining whether the signature is enriched in
pathway key actors. Given the M genes measured on a microarray, our signature is defined as a
subset of length n of these genes, and a given pathway is defined as another subset of length K of
these genes. The probability of having y genes in common between our signature and a pathway
is given by the hypergeometric distribution:
P(Y = y) =
(n
y
)(M−n
K−y
)(M
K
) .
This approach requires a pre-defined set of pathways to analyze. Several databases exist to-
day and the Kyoto Encyclopedia of Genes and Genomes (KEGG [13]) is often taken as a reference.
The problem with the analysis of pathways is that they do not represent clearly distinct entities
and two pathways can involve common genes and hence share a common biological information.
Consequently a set of genes can be responsible for the positive results of several pathways.
In order to ease the interpretation of Pathway Analysis results, we propose to summarize the set
of pathways found significant because of the same genes into a reduced set of "core pathways"
(each core pathway represented by a set of pathways). In practice we apply a Hierarchical
Clustering algorithm on a binary matrix, that contains the genes in row and the pathways in
column, summarizing the membership of each gene to each pathway. Dissimilarity, which
accounts for pairwise differences between the pathways, is assessed by using a binary metric, also
known as the Jaccard distance. Finally, from this dissimilarity matrix we perform a Hierarchical
Agglomerative Clustering using Ward’s criterion.
Each core pathway defines a gene cluster which will be used in the next step for inferring the
regulation network.
Step 3: Network Inference from biological prior knowledge
The last step of the procedure consists in inferring a part of the regulation network using
the transcriptomic data from all available conditions and from the prior structure exhibited in
the pathway analysis. This last step relies on a Gaussian Graphical Model, taking advantage of
the relation existing between conditional independence and the concentration matrix. Variables
(i.e. genes) X i and X j with i 6= j are independent conditional on all other variables indexed
by P\{i, j}, if and only if the entry (Σ−1)i j is zero. The inverse of the covariance matrix
K = (Ki j)(i, j)∈P2 = Σ−1, known as the concentration matrix, thus describes the conditional
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independence structure of X . Moreover, each entry Ki j, is directly linked to the partial correlation
coefficient ri j|P\{i, j} between variables X i and X j. The inferred graph is described by the
adjacency matrix defined by the nonzero elements of the concentration matrix.
Merging different experimental conditions from transcriptomic data is a common practice in
GGM-based inference methods [31]. This process enlarges the number of observations available
for inferring interactions. However, GGMs assume that the observed data form an independent
and identically distributed (i.i.d.) sample. But assuming that the merged data is drawn from a
single Gaussian component is obviously wrong, and is likely to have detrimental side effects in
the estimation process.
In this paper, we assume that the distributions of these different conditions have strong common-
alities. We thus propose to estimate these graphs jointly. In this context, the multi-task learning
provides a convenient framework [5]. This approach allows to overcome the difficulties arising
from the scarcity of data in each experimental condition by coupling the estimation problems.
Moreover we take advantage of the previously exhibited gene clusters to put some prior structure
on the inferred network. We assume that the edges of the graph defined by the nonzero elements
of the concentration matrix are distributed among a set Q = {1, . . . ,Q} of given overlapping
clusters. For any gene i, the indicator variable Ziq is equal to 1 if i ∈ q and 0 otherwise, hence
describing to which cluster the gene i belongs. The structure of the graph is thus described by the
matrix Z= (Ziq)i∈P,q∈Q.
Thus the group structure over the Q gene clusters and the structure over the 2 conditions lead
to estimating the 2 concentration matrices which are the solutions of the following penalized
log-likelihood maximization problem:
max
K(c),c∈1,2
2
∑
c=1
L
(
K(c);X
)
−λ ∑
i, j∈P
i 6= j
ρZiZ j

(
2
∑
c=1
[
K(c)i j
]2
+
)1/2
+
(
2
∑
c=1
[
K(c)i j
]2
−
)1/2 , (1)
where [u]+ = max(0,u) and [u]− = min(0,u) and the coefficients of the penalty are defined as:
ρZiZ j =

∑
q,`∈Q
ZiqZ j`
1
λin
, if i 6= j, and q= `,
∑
q,`∈Q
ZiqZ j`
1
λout
, if i 6= j, and q 6= `,
1, otherwise,
(2)
and
L (K(c);X) =
n
2
logdet(K(c))− n
2
Tr(S(c)K)+C,
with S(c) the empirical covariance matrix relative to condition c and C a constant term.
The first part of the criterion ∑2c=1L
(
K(c);X
)
consists in the sum of the log-likelihoods of the
two concentration matrices given the observations. The second part of the criterion is a penalty,
which considers two types of edges: edges between two genes belonging to the same core pathway
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are penalized with a coefficient 1/λin and edges between two genes which are never present
together in a pathway are penalized with a coefficient 1/λout.
The basic form of the penalty has been proposed in [2] where it has been shown via simulations
that the knowledge of an existing group structure was indeed improving the estimation of the
non-zeros entries of the concentration matrix. The current form of the penalty [5] encourages
co-regulation of the same sign across the two conditions. Specifically, co-regulation encompasses
up-regulation and down-regulation and the type of regulation is not likely to be inverted across
assays: in terms of partial correlations, sign swaps are very unlikely.
3. Application
We apply our approach to the study of the response to chemotherapy in breast cancers. The
pathologic Complete Response (pCR), defined as the absence of disease in both the breast and
lymph nodes, is used as an early surrogate marker of treatment efficacy. Most studies on response
to chemotherapy have considered breast cancer as a single homogeneous entity. However, it is a
complex disease that has a molecular and cellular heterogeneity that should not be overlooked in
such studies. Perou et al. [24] were the first to report evidence for breast cancer tumor subtypes
based upon gene expression profiles. Since the various tumor subgroups were re-evaluated and
breast cancers have been classified into five molecular classes: luminal A and B, basal, ErbB2+,
and normal-like subgroups [28, 29]. These subtypes differ markedly in prognosis and in the
repertoire of therapeutic targets they express [20]. Within these five groups, basal-like breast
cancers, quickly became a subtype of interest because of its features. Indeed it is associated with
poor prognosis and characterized by its aggressive behavior.
Many reports have demonstrated that basal-like tumors are chemo-sensitive. This particular
subtype of breast cancer correlated with significantly higher pCR rates when compared to other
subtypes [18]. Nevertheless, basal tumors harboring homogeneous clinical and pathologic features
may exhibit highly variable response to chemotherapy. It raises new questions to biologists such
as how to explain the differences between patients who achieve a pCR from those that do not
(not-pCR), and which are the molecular mechanisms involved in chemo-sensitivity or resistance ?
We demonstrate that our approach based on Pathway Analysis and Network Inference can
provides effective tools to address such questions of biological and clinical interests. To do so,
we investigate the dataset proposed by Hess et al. [11] including 133 breast cancer samples for
which the pCR status is known. Gene expression profiling has been made based on the Affymetrix
U133A microarray. Following the methodology described in Sorlie et al. [28], we identify 29
basal tumors from the 133 samples, divided into 15 pCR and 14 not-pCR.
Step 1 - Comparison of the gene expression profiles between the pCR and not-pCR samples
yields about 100 genes with statistically significant differences (at a 10−3 level). We add 30 key
regulatory genes identified from the STRING database. These 130 genes represent the molecular
signature of the pCR in our 29 basal tumors.
Step 2 - The Pathway Analysis driven from the molecular signature identified 22 significant
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KEGG pathways (at a 5% level). The Hierarchical Clustering of these pathways lead to 6 core
pathways that summarize 6 main, distinct and clear biological processes involved in the mecha-
nisms of response to treatment in basal tumors (Figure 3). For instance, one core pathway includes
the VEGF, mTOR and IL8 signaling pathways, all associated with angiogenesis, the new blood
vessel formation process required for tumor progression. Consequently, such results lead us to
relate this core pathway to angiogenesis.
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Figure 3. Core pathways. From the Hierarchical Clustering we identify 6 core pathways.
Figure 3-A highlights the core pathways related to tumor cell growth and proliferation
mechanism and Figure 3-B highlights the core pathways associated with angiogenesis activity.
Step 3 - The 6 core pathways are taken as a biological prior for driving the Network Inference
using the R package SIMoNe. A particularly interesting network subpart is shown on Figure 4,
wich includes many genes known to be associated with breast cancer (for instance: mTOR, WNT,
VEGF, AKT1...).
In particular, it has been shown that the CALM3 gene regulates the activity of AKT1 in breast
tumors [6]. Our network suggests that this regulation occurs only in the pCR condition, and hence,
may be broken for not-pCR tumors.
4. Discussion and conclusion
The ability to infer networks from high-throughput genomic data is one of the most promising
applications of Systems Biology. In this paper, we propose a global framework to infer networks
on the basis of a biological informative prior over network structures. It has the advantage to
reduce the space of possible network structures to investigate, and to propose a more relevant
network in order to facilitate the interpretation of its edges. Network Inference is done using the
SIMoNe algorithm developed by Chiquet et al. [5] and based on a weighted Lasso criterion in a
Gaussian Graphical Model framework.
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Angiogenesis 
WNT signaling 
Cell growth 
Axon guidance 
Adherens junction 
Calcium signaling 
Edges present in both pCR and not‐pCR networks 
Edges present in pCR network only 
Edges present in not‐pCR network only 
Figure 4. Inferred graph from the Hess cohort. The figure displays an enlarged view of a
network subpart. The black dashed edges are present in both pCR and not-pCR networks. In red
are the edges inferred only in the not-pCR network and conversely, the green edges are only
inferred in the pCR network.
In this context, determining the biological prior to use is not a simple task. To this purpose,
we define an informative prior using Pathway Analysis that allows, from molecular signature, to
identify which are the main cellular mechanisms associated with a condition of interest. Many
public domain repositories exist for storing biological pathways, each based on its own set of
conventions. Thus pathways are not consistent among databases and the same pathway can
present several definitions that vary greatly in quality and completeness [1]. Pathway Analysis is
hence database dependent. However our approach overcomes this limitation in two points: i) the
definition of core pathways from the molecular signature makes our analysis less sensitive to the
strict definition of pathways found in the databases and ii) it is possible to adjust the weighted
penalization according to the confidence we have in each pathway definition.
The core of such an approach, combining both Pathway Analysis and Network Inference, is
the selection of the most informative set of genes to discriminate between the two conditions
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(i.e. the molecular signature). The relevance of the biological findings at the end of the analysis
greatly depends on this signature. In consequence, as a first step of our global Network Inference
process, we propose an improved Differential Analysis. In particular, we aim to increase the
reproductibility of the signature by removing potential outliers and identifying modules of genes
via functional partners identification. It allows to include some well-studied genes (such AKT1)
not detected in the differential analysis. However the noise inherent to PPI data is one of the main
limitations of this approach. Indeed, only few protein interactions are confirmed by the HPRD
(Human Protein Reference Database). These high noise levels reduce the accuracy of functional
partners identification. By restricting our study to high-confidence score interactions, we focused
on the most biologically relevant interactions. However it introduces a bias into our approach by
selecting the most studied and documented proteins. Then, the functional partners identification
step is highly dependent on the quality and the amount of data available.
The functional partners identification method still needs to be further improved and explored. In
particular, we have to develop an evaluation strategy to better assess the contribution of such a
method in identifying genes of interest.
Our application on breast cancer data highlights key regulations in cancer progression and
response to treatment. The co-expression of AKT1 and CALM3 that occurs specifically in the
group responding to chemotherapy is a good example. Such results can be a starting point of
more important applications at the biological and clinical levels.
Finally, the regulation of gene expression is a complex process resulting from several regula-
tory mechanisms occurring at distinct steps of the biological system (miRNA, eQTL, genomic
alterations and epigenetic factors for instance) and gene expression data enables us to understand
a limited part of the whole system. In this context, the inference of networks from heterogeneous
biological data, such as eQTL, is a very promising topic to develop in the near future.
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